Literature DB >> 6247056

Pancreatic alpha cell tumors: case report and review of the literature.

J Lokich, N Anderson, A Rossini, W Hadley, M Federman, M Legg.   

Abstract

Twenty-eight cases of alpha cell tumors of the pancreatic islets have been reported. The clinical features include typical skin rash (termed migratory necrolytic erythema) and stomatitis with anemia, abnormal glucose tolerance, and weight loss. The time course of the disease is variable but the clinical syndrome may be present for up to 15 years (median five years) before discovery of the tumor. In 3 patients, cure was achieved by surgical resection, and in 17 patients in whom metastatic sites were evaluable, 16 involved the liver. Six patients have received chemotherapy: 4 with streptozotocin (STZ); 1 with dimethyl triazeno imidazole carboxamide (DTIC); and 2 with 5-fluorouracil. All 4 patients receiving STZ responded to therapy with objective regression of the tumor and in 3 the dermatitis syndrome receded as well. The selectivity of the STZ for beta cells observed in animals is contrasted with the specific antitumor activity of STZ for alpha as well as beta and delta cell tumors in man.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247056     DOI: 10.1002/1097-0142(19800515)45:10<2675::aid-cncr2820451032>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Endoscopic findings of a pancreatic glucagonoma.

Authors:  A G Guirado; P Sanchez-Fayos; O Bosch; M J Relloso; C Rivas; J C Porres
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

2.  Immunohistochemical identification of factor X-like antigen in the A cells of the normal human pancreas.

Authors:  C Betterle; A Trevisan; A Girolami
Journal:  Diabetologia       Date:  1982-09       Impact factor: 10.122

3.  Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor.

Authors:  S Del Prato; A Rovira; P Tessari; A Avogaro; R Nosadini; I Valverde; R Trevisan; A Tiengo
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.